[go: up one dir, main page]

HK1201719A1 - Pharmaceutical solid preparation comprising benzazepines and production method thereof - Google Patents

Pharmaceutical solid preparation comprising benzazepines and production method thereof Download PDF

Info

Publication number
HK1201719A1
HK1201719A1 HK15101484.4A HK15101484A HK1201719A1 HK 1201719 A1 HK1201719 A1 HK 1201719A1 HK 15101484 A HK15101484 A HK 15101484A HK 1201719 A1 HK1201719 A1 HK 1201719A1
Authority
HK
Hong Kong
Prior art keywords
solid preparation
pharmaceutical solid
particle diameter
weight
methyl
Prior art date
Application number
HK15101484.4A
Other languages
English (en)
Chinese (zh)
Inventor
信介 中川
海 鈴木
海 铃木
正志 向井
Original Assignee
大塚制药株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40070798&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1201719(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 大塚制药株式会社 filed Critical 大塚制药株式会社
Publication of HK1201719A1 publication Critical patent/HK1201719A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK15101484.4A 2007-06-21 2010-06-18 Pharmaceutical solid preparation comprising benzazepines and production method thereof HK1201719A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-163551 2007-06-21
JP2007163551 2007-06-21

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
HK10106088.8A Addition HK1139324A (en) 2007-06-21 2008-06-20 Pharmaceutical solid preparation comprising benzazepines and production method thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
HK10106088.8A Division HK1139324A (en) 2007-06-21 2008-06-20 Pharmaceutical solid preparation comprising benzazepines and production method thereof

Publications (1)

Publication Number Publication Date
HK1201719A1 true HK1201719A1 (en) 2015-09-11

Family

ID=40070798

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15101484.4A HK1201719A1 (en) 2007-06-21 2010-06-18 Pharmaceutical solid preparation comprising benzazepines and production method thereof

Country Status (24)

Country Link
US (4) US10905694B2 (fr)
EP (1) EP2167046B1 (fr)
JP (1) JP5289338B2 (fr)
KR (1) KR101526625B1 (fr)
CN (3) CN101686941A (fr)
AR (1) AR067077A1 (fr)
AT (1) ATE489944T1 (fr)
AU (1) AU2008264445B2 (fr)
CA (1) CA2689467A1 (fr)
CY (1) CY1111939T1 (fr)
DE (1) DE602008003816D1 (fr)
DK (1) DK2167046T3 (fr)
ES (1) ES2354030T3 (fr)
HK (1) HK1201719A1 (fr)
HR (1) HRP20100676T1 (fr)
IL (1) IL202179A (fr)
MX (1) MX2009014193A (fr)
MY (1) MY147599A (fr)
PL (1) PL2167046T3 (fr)
PT (1) PT2167046E (fr)
RU (1) RU2466717C2 (fr)
SI (1) SI2167046T1 (fr)
TW (1) TWI405574B (fr)
WO (1) WO2008156217A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102293734A (zh) 2010-06-25 2011-12-28 江苏恒瑞医药股份有限公司 托伐普坦固体分散体及其制备方法
CN102552278A (zh) * 2010-12-23 2012-07-11 天津泰普药品科技发展有限公司 一种提高难溶性药物托伐普坦溶出度的药物组合物
CN102228423B (zh) * 2011-06-29 2013-03-06 重庆市庆余堂制药有限公司 托伐普坦口服固体药物组合物及其制备方法
JP6057628B2 (ja) * 2012-09-06 2017-01-11 クリーンケミカル株式会社 人工透析装置のプライミング方法
TWI660748B (zh) 2013-03-01 2019-06-01 日商大塚製藥股份有限公司 用於口服投藥之包含非晶型托伐普坦（Ｔｏｌｖａｐｔａｎ）的懸浮液
TW201605488A (zh) 2013-10-15 2016-02-16 大塚製藥股份有限公司 用以預防及／或治療多囊腎病之藥物
JP6761695B2 (ja) 2016-08-16 2020-09-30 信越化学工業株式会社 低置換度ヒドロキシプロピルセルロース及び固形製剤
JP6838446B2 (ja) * 2017-03-22 2021-03-03 ニプロ株式会社 トルバプタン製剤およびその製造方法
JP7352175B2 (ja) * 2019-12-25 2023-09-28 ニプロ株式会社 トルバプタン製剤
CN111888335A (zh) * 2020-08-21 2020-11-06 福安药业集团重庆礼邦药物开发有限公司 一种托伐普坦的药物固体制剂及制备方法
US20240366625A1 (en) 2021-06-02 2024-11-07 Esperion Therapeutics, Inc. Compositions containing and therapies using bempedoic acid and tolvaptan
EP4321154A1 (fr) 2022-08-03 2024-02-14 Sanovel Ilac Sanayi Ve Ticaret A.S. Comprimé de tolvaptan et au moins un liant traité par granulation par pulvérisation
CN120115300B (zh) * 2025-05-13 2025-08-05 洛阳栾川钼业集团股份有限公司 滑石抑制剂及其制备方法及从高滑石辉钼矿的泥精矿中回收钼的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2071511A (en) * 1934-10-01 1937-02-23 Reed & Carnrick Enteric coating
DE122009000062I2 (de) 1989-10-20 2011-01-13 Otsuka Pharma Co Ltd Benzoheterozyklische verbindungen
TW430561B (en) * 1995-12-20 2001-04-21 Gea Farmaceutisk Fabrik As Rapid release tablet composition comprising tolfenamic acid or a pharmaceutically acceptable salt thereof as active ingredient and a method of preparing such tablet
JPH09278656A (ja) * 1996-02-05 1997-10-28 Sankyo Co Ltd 経口投与用５α−リダクターゼ阻害製剤及びその製造方法
DE69740161D1 (de) * 1996-11-15 2011-05-12 Ajinomoto Kk Nateglinide-Tablettenzubereitungen
JP4210355B2 (ja) * 1997-07-03 2009-01-14 大塚製薬株式会社 固形製剤組成物
EP1121103B1 (fr) * 1998-05-18 2006-12-20 Takeda Pharmaceutical Company Limited Comprimes se desintegrant dans la bouche comprenant une benzimidazole
EP1054019A1 (fr) * 1999-05-18 2000-11-22 Shin-Etsu Chemical Co., Ltd. Hydroxypropylcellulose possédant un faible degré de substitution
EP1385486A4 (fr) * 2001-04-18 2006-05-17 Nostrum Pharmaceuticals Inc Nouvel enrobage de composition pharmaceutique a liberation lente
JP2004026861A (ja) * 2002-06-21 2004-01-29 Shin Etsu Chem Co Ltd 濾過性に優れる水溶性セルロースエーテル及びその選定方法
JP4684545B2 (ja) * 2002-09-26 2011-05-18 大日本住友製薬株式会社 溶出性の良好なイソキサゾール誘導体経口製剤
TWI322689B (en) * 2003-02-24 2010-04-01 Otsuka Pharma Co Ltd Method for treating severe heart failure and medicament therefor
WO2004087109A1 (fr) * 2003-03-27 2004-10-14 Hisamitsu Pharmaceutical Co., Inc. Preparations medicamenteuses orales liberees au niveau du colon, preparations medicamenteuses orales pour traiter le cancer du colon et preparations medicamenteuses orales pour traiter la colite
TW200507882A (en) * 2003-07-17 2005-03-01 Kyowa Hakko Kogyo Kk Solid formulations
US8158146B2 (en) * 2005-09-28 2012-04-17 Teva Pharmaceutical Industries Ltd. Stable combinations of amlodipine besylate and benazepril hydrochloride

Also Published As

Publication number Publication date
US20230321113A1 (en) 2023-10-12
KR20100038386A (ko) 2010-04-14
JP2010530355A (ja) 2010-09-09
PT2167046E (pt) 2011-02-10
BRPI0813100A2 (pt) 2014-12-23
RU2466717C2 (ru) 2012-11-20
ES2354030T3 (es) 2011-03-09
IL202179A (en) 2012-10-31
ATE489944T1 (de) 2010-12-15
JP5289338B2 (ja) 2013-09-11
HRP20100676T1 (hr) 2011-01-31
CN103989644A (zh) 2014-08-20
CN103463095A (zh) 2013-12-25
DK2167046T3 (da) 2011-01-31
IL202179A0 (en) 2010-06-16
MX2009014193A (es) 2010-01-28
RU2010101797A (ru) 2011-07-27
CN101686941A (zh) 2010-03-31
WO2008156217A3 (fr) 2009-02-26
WO2008156217A2 (fr) 2008-12-24
TW200911270A (en) 2009-03-16
US20210069207A1 (en) 2021-03-11
MY147599A (en) 2012-12-31
DE602008003816D1 (de) 2011-01-13
CY1111939T1 (el) 2015-11-04
US10905694B2 (en) 2021-02-02
CA2689467A1 (fr) 2008-12-24
US20210113582A1 (en) 2021-04-22
US20100323006A1 (en) 2010-12-23
KR101526625B1 (ko) 2015-06-05
EP2167046B1 (fr) 2010-12-01
AU2008264445B2 (en) 2013-06-27
AU2008264445A1 (en) 2008-12-24
EP2167046A2 (fr) 2010-03-31
PL2167046T3 (pl) 2011-05-31
AR067077A1 (es) 2009-09-30
SI2167046T1 (sl) 2011-03-31
TWI405574B (zh) 2013-08-21

Similar Documents

Publication Publication Date Title
HK1201719A1 (en) Pharmaceutical solid preparation comprising benzazepines and production method thereof
CN101868228B (zh) 口腔内崩解片
CN101945657B (zh) 具有改善的溶出性的片剂
JP5827299B2 (ja) イルベサルタンとアムロジピンまたはその塩を含有する医薬組成物
AU2006250340A1 (en) Pharmaceutical composition
EP2303240A1 (fr) Compositions pharmaceutiques comprenant du 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phényl]-1,3-oxazolidin-5-yl}-méthyl)-2-thiophènecarboxamide
JP2007031451A (ja) ラソフォキシフェン錠剤およびそのコーティング
WO2017170858A1 (fr) Préparation orale présentant une exceptionnelle aptitude à l'élution
CA2874779A1 (fr) Composition pharmaceutique d'entecavir, et procede de fabrication
JP2013237651A (ja) ピタバスタチンの口腔内崩壊錠
CN105407875A (zh) 包含异烟肼颗粒和利福喷汀颗粒的呈包衣片剂形式的抗结核病的稳定的药物组合物及其制备方法
HK1139324A (en) Pharmaceutical solid preparation comprising benzazepines and production method thereof
HK1190938A (en) Pharmaceutical solid preparation comprising benzazepines and production method thereof
WO2020122244A1 (fr) Comprimé, et procédé de fabrication de celui-ci
JP6321131B2 (ja) アムロジピン含有配合錠の溶出性改善方法
WO2018130943A1 (fr) Composition pharmaceutique orale de lurasidone et sa préparation
MXPA06010805A (es) Formulacion de claritromicina de libracion prolongada.
TWI523842B (zh) 托伐普坦固體分散體及其製備方法
HK40000065A (en) Oral preparation having exceptional elutability
BRPI0813100B1 (pt) Preparação sólida farmacêutica e método de produção da mesma